In a recent study conducted at the Columbia University Medical Center (CUMC) revealed the ability of adjacent genes to cause cancer by fueling the activity of the mitochondria. In 2012, CUMC’s research had shed light on the fusion of TACC3 and FGFR3 genes which caused the most adverse form of brain cancer called glioblastoma. However, a contemporary research inference points to the direct relationship of cancers and tumors to mitochondrial activity.
Analyzing the TACC-FGFR3 Gene Combination to Understand Cancer Propulsion
The researchers studied the activity of numerous genes in cancer cells with and without the presence of TACC3-FGFR3 fusion. It was inferred from the study that the fusion of TACC3-FGFR3 enhanced the number of cancer cells and also escalated the activity rate of mitochondria. Furthermore, cancer cells require commendable energy to amplify their attacks, and they gain this energy via the mitochondrial activity. The researchers believe that the results of the research are an important standpoint to understand the cause and effects operational between cancer genes and mitochondrial mechanisms. Hence, it is an important advancement towards inhibiting the growth of cancers.
Devising Combat Mechanisms to Inhibit Cancer Growth
It was found that the use of mitochondrial inhibitors to treat human brain cells that exhibited the TACC3-FGFR3 gene combination could cut the supply of energy to cancer cells and reduce the growth rate of tumors. The head of the research group believes that FGFR3-TACC3 tumors can be treated by following a two-fold approach. The introduction of mitochondrial inhibitors, that would in turn inhibit the fueling of cancer cells, is also on the cards of the medical researchers. The research study has opened doors to a number of other initiatives that could take us closer to the effective treatment of tumors and cancers.